John A. Oates

Follow

Generating author description...

All published works

Action	Title	Year	Authors
+	Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework	2001	Arthur J. Atkinson Wayne A. Colburn Victor G. DeGruttola David L. DeMets Gregory J. Downing Daniel F. Hoth John A. Oates Carl C. Peck Robert T. Schooley Bert Spilker
+	Regulatory Trends in Early Clinical Trials	1983	John A. Oates
+	A scientific rationale for choosing patients rather than normal subiects for Phase I studies	1972	John A. Oates

Common Coauthors

Coauthor	Papers Together
Scott L. Zeger	1
Robert T. Schooley	1
Wayne A. Colburn	1
David L. DeMets	1
Carl C. Peck	1
Gregory J. Downing	1
Bert Spilker	1
Janet Woodcock	1
Daniel F. Hoth	1
Victor G. DeGruttola	1
Arthur J. Atkinson	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+	Surrogate endpoints: A basis for a rational approach	1992	Jean‐Pierre Boissel Jean‐Philippe Collet P Moleur M. Haugh	1
+	Surrogate Markers in AIDS: Where Are We? Where Are We Going?	1992	Stephen W. Lagakos Daniel F. Hoth	1
+ PDF Chat	Efficacy Measures: Surrogates or Clinical Outcomes?	1996	John W. Blue Wayne A. Colburn	1
+	Meta-analysis for the evaluation of potential surrogate markers	1997	Michael J. Daniels Michael D. Hughes	1
+	Surrogate End Points in Clinical Trials: Are We Being Misled?	1996	Thomas R. Fleming	1
+ PDF Chat	Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease	1999	Bruce M. Psaty	1
+	Statistical validation of intermediate endpoints for chronic diseases	1992	Laurence S. Freedman Barry I. Graubard Arthur Schatzkin	1
+	ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER	1997	D. Y. Lin Thomas R. Fleming Victor De Gruttola	1
+	Surrogate endpoints in clinical trials: Definition and operational criteria	1989	Ross L. Prentice	1
+	Evaluating surrogate markers.	1995	Michael D. Hughes Victor DeGruttola Seth L. Welles	1